Verition Fund Management LLC Taysha Gene Therapies, Inc. Transaction History
Verition Fund Management LLC
- $23.6 Billion
- Q4 2024
A detailed history of Verition Fund Management LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 34,098 shares of TSHA stock, worth $54,556. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,098Holding current value
$54,556% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding TSHA
# of Institutions
130Shares Held
151MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$32 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$28.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$18.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$17.4 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$16.7 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $77.4M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...